دورية أكاديمية
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.
| العنوان: | Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. |
|---|---|
| المؤلفون: | Gagelmann, Nico, Eikema, Diderik-Jan, Stelljes, Matthias, Beelen, Dietrich, De Wreede, Liesbeth C., Mufti, Ghulam, Knelange, Nina Simone, Niederwieser, Dietger, Friis, Lone S, Ehnninger, Gerhard, Nagler, Arnon, Yakoub-Agha, Ibrahim, Meijer, Ellen, Ljungman, Per, Maertens, Johan, Kanz, Lothar, Lopez-Corral, Lucia, Brecht, Arne, Craddock, Charles, Finke, Jurgen, Cornelissen, Jan J, Bernasconi, Paolo, Chevallier, Patrice, Sierra, Jorge, Robin, Marie, Kroger, Nicolaus |
| المساهمون: | CHU Lille, Inserm, Université de Lille, Lille Inflammation Research International Center (LIRIC) - U995, Lille Inflammation Research International Center - U 995 LIRIC |
| سنة النشر: | 2023 |
| المجموعة: | LillOA (Lille Open Archive - Université de Lille) |
| الوصف: | The aim of this study was to develop and validate a clinical and transplant-specific prognostic score using data from a large cohort of patients with myelodysplastic syndromes reported to the European Society for Blood and Marrow Transplantation registry. A Cox model was fitted to detect clinical and transplant-related variables prognostic of outcome. Then, cross-validation was performed to evaluate the validity and consistency of the model. Seven independent risk factors for survival were identified: age ≥50 years, matched unrelated donor, Karnofsky Performance Status <90%, very poor cytogenetics or monosomal karyotype, positive cytomegalovirus status of the recipient, blood blasts >1%, and platelet count ≤50 × 10 /L prior to transplantation. Incorporating these factors into a four-level risk score yielded hazard ratios for death, with low-risk (score of 0-1) as reference, of 2.02 (95% CI: 1.41-2.90) for the intermediate-risk group (score of 2-3), 3.49 (95% CI: 2.45-4.97) for the high-risk group (score of 4-5), and 5.90 (95% CI: 4.01-8.67) for the very high-risk group (score of >5). The score was predictive of survival, relapse-free survival, relapse, and non-relapse mortality ( <0.001, respectively). Cross-validation yielded significant and reproducible improvement in prognostic ability with C-statistics being 0.609 (95% CI: 0.588-0.629) 0.555 for the registry and 0.579 for the Center for Blood and Marrow Transplant Research registry. Prediction was even further augmented after applying a nomogram using age and platelets as continuous variables showing C-statistics of 0.628 (95% CI: 0.616-0.637). In conclusion, compared to existing prognostic systems, this proposed transplant-specific risk score offers improved performance with respect to post-transplant risk stratification in myelodysplastic syndromes. ; 104 |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/octet-stream; application/rdf+xml; charset=utf-8; application/pdf |
| اللغة: | English |
| العلاقة: | Haematologica; http://hdl.handle.net/20.500.12210/13758Test |
| الإتاحة: | https://doi.org/20.500.12210/13758Test https://hdl.handle.net/20.500.12210/13758Test |
| حقوق: | Attribution-NonCommercial 3.0 United States ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.EED2BF6C |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |